

ATTORNEY DOCKET NO
25481- P001US

PATENT
U.S. Ser. No. 09/ 902,176

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant; Schreiber
Serial No.: 09/902,176
Filed: July 10, 2001
Art Unit: 1645
Confirmation No.: 7507

Title: DIAGNOSTIC USE OF POLYMORPHISMS IN THE GENE CODING FOR THE
TNF RECEPTOR II AND METHOD FOR DETECTING NON-RESPONDERS TO ANTI
TNF THERAPY

Director of Patents
Box Amendment
Washington, D.C. 20231.

Certificate of Mailing

This document is being deposited with the U.S. Postal Service as U.S. first class mail with sufficient postage, in an envelope addressed to the Dir. for Patents, Washington, D.C. 20231, on the date indicated below.

[Signature]
Signature

Stapleton
Printed Name

Dec 21, 2001
Date

INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits the following references in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of the references cited in the attached PTO-1449 are enclosed for the convenience of the Examiner. Furthermore, pursuant to 37 C.F.R. § 1.97(g) and (h), no representation is made that this is material to patentability of the present application or that a search has been made.


Applicant hereby submits that claims of Applicant's above-referenced patent application are patentably distinguishable from these references..

The Applicant considers that no fees are due. However, the Commissioner is hereby authorized to charge any fees or credit any overpayment to Deposit Account Number 23-2426 of WINSTEAD SECHREST & MINICK P.C.

Respectfully submitted,
WINSTEAD SECHREST & MINICK
Attorneys for Applicant

5400 Renaissance Tower
1201 Elm Street
Dallas, Texas 75270
(214) 745-5374
Attorney's Docket: 25481- P001US
Date December 19, 2001

By: James J. Murphy
James J. Murphy
Reg. No. 34,503



Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number	09/902,176
Filing Date	July 10, 2001
First Named Inventor	Schreiber
Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	25481-P001US

Sheet 1 of 2

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		WO 00/31293	06-02-2000	Morris	Whole document	

Date
Considered

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/902,176		
		Filing Date	July 10, 2001		
		First Named Inventor	Schreiber		
		Group Art Unit	1645		
		Examiner Name	Not yet assigned		
Sheet	2	of	2	Attorney Docket Number	25481-P001US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		SMITH et al.; Human Tumor Necrosis Factor Receptor mRNA; Database EMHUM6 'Online!'; ID HSNFR, June 1990	
		SYNERGEN, Inc.; 40kD TNF Inhibitor Precursor; Database GCG_GENESEQ_P 'Online!'; R11001 January 1991	
		SMITH; Fibroblast Derived TNF-R; Database GCG_GENESEQ_P 'Online!'; ID: R42058, April 1994	
		BELTINGER, et al.; Physical Mapping and Genomic Structure of the Human TNFR2 Gene; Genomics 35, 94-11 (1996); Article No. 0327; 1996	
		RAU, et al.; Polymorphisms of Tumor Necrosis Factor Receptor 2 are Not Associated with Insulin-Dependent diabetes Mellitus or Graves' Disease; Tissue Antigens; Vol 49, No. 5, 1997, pages 535-536	
		VAN DEVENTER; Immunomodulation of Chron's Disease Using TNF-alpha Neutralizing Monoclonal Antibodies; Clinical Nutrition, GB, Churchill, Livingston, London; 1997	
		CHO, et al; Identification of Novel Susceptibility Loci for Inflammatory Bowel disease on Chromosomes 1p, 3q, and 4q: Evidence for Epistasis Between 1p and IBD1; Proceedings of the National Academy of Sciences of the United States; vol 95, no. 13; June 23, 1998; pages 7502-7507	
		KOMATA, et al; Association of Tumor Necrosis Factor Receptor 2 (TNFR2) Polymorphism with Susceptibility to systemic Lupus Erythematosus; Tissue Antigens, Vol 53, No. 6; June 1999; pages 527-533	
		PANTELEDIS, et al.; Polymorphic Analysis of the High-Affinity Tumor Necrosis Factor Receptor 2; Tissue Antigens, Vol 54, Dec. 1999; pages 585-591	
		AL-ANSARI, et al.; Tumor Necrosis Factor Receptor II (TNFRII) Exon 6 Polymorphism in systemic Lupus Erythematosus; Tissue Antigens, Vol 55, No. 1; January 2000, pages 97-99	
		LOUIS, et al.; Tumour Necrosis Factor (TNF) Gene Polymorphism in Crohn's Disease (CD): Influence on Disease Behaviour?; Clinical and Experimental Immunology, Vol 119, No. 1, January 2000; pages 64-68	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 29 2002
TECH CENTER 1600/2900